Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850061 | 0.87 | SMN1; SMN2 (0.41) | HDAC8MPOADORA3ADORA2AL3MBTL1 | |
| SCHEMBL1852868 | 0.86 | GRM2 (0.45) | HDAC8MPOGRM2KCNH2 | |
| SCHEMBL1855398 | 0.86 | NOS1 (0.55) | HDAC8MPOADORA3ADORA2AADORA1 | |
| SCHEMBL3222034 | 0.84 | L3MBTL1 (0.49) | HDAC8ADORA3ADORA2AADORA1GRM2 | |
| SCHEMBL17221449 | 0.83 | HDAC1 (0.46) | HDAC8 | |
| SCHEMBL11155364 | 0.82 | MPO (0.46) | HDAC8MPOADORA3ADORA2AADORA1 | |
| SCHEMBL1169684 | 0.82 | MPO (0.46) | MPOADORA3ADORA2AADORA1TGFBR1 | |
| SCHEMBL4792680 | 0.82 | MPO (0.46) | MPOADORA3ADORA2AADORA1TGFBR1 | |
| SCHEMBL24879334 | 0.81 | ADORA3 (0.42) | MPOADORA3ADORA2AADORA1TGFBR1 | |
| SCHEMBL4791000 | 0.81 | ADORA3 (0.45) | MPOADORA3ADORA2AADORA1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| CN-102775350-A | Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors | ABBOTT LAB | 2012-11-14 | — | — | CN | disclosed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| CN-101466374-B | Methods for preparing indazolyl ureas that inhibit vanilloid subtype 1(VR1) receptor | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| CN-102321025-A | Preparation suppresses the method for the indazolyl urea of vanilloid subtype type 1 (VR1) acceptor | ABBOTT LAB | 2012-01-18 | — | — | CN | disclosed |
| CN-102140081-A | Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors | ABBOTT LAB | 2011-08-03 | — | — | CN | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2011-02-17 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| CN-101466374-A | Methods for preparing indazolyl ureas that inhibit vanilloid subtype 1(VR1) receptor | ABBOTT LAB (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-2012779-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | HDAC8 573/4885MPO 3078/4885ADORA3 591/4885 |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | UTS2R, VIPR1, VRK1 | HDAC8 3537/4885MPO 4658/4885ADORA3 291/4885 |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | UTS2R, VIPR1, VRK1 | HDAC8 3490/4885MPO 4616/4885ADORA3 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.